Novavax, Inc. (NASDAQ:NVAX) traded 82,800,444 shares on last trading day with closing price of $1.49. Movements above 70 are interpreted as indicating overbought conditions; conversely, movements under 30 reflect oversold conditions. Analyst’s mean target price for Gilead Sciences Inc. One research analyst has rated the stock with a sell rating, six have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Its previous fifty two week high was $6.4 and moved down -24.83% over the same period, now having a market cap around $195.14 million. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.04.
Advertisement
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with MarketBeat.com’s FREE daily email newsletter.
According to Chardan Capitals price target of 1.5 on the company’s stock this indicates the broker now believes there is an increase of 0.67% from Novavax’s current price of 1.49. The stock now has an average rating of Hold and a consensus price target of $8.78. 5 have given the stock a Hold rating, 0 as Underperform and 0 as Sell. According to analysts minimum EPS for the current quarter is expected at $-0.29 and can go high up to $-0.23.
On technical side, moving averages may help to distinguish direction of tendencies, and they might also be used to set levels of sustenance and resistance. Novavax, Inc. (NASDAQ:NVAX) shares were trading -86.07% below from the 52-week high mark of $10.70 and +28.45% above from the 52-week bottom of $1.16.
Novavax, Inc. NASDAQ:NVAX has a 50 day moving average of 7.42 Dollars and the 200 Day Moving Average price is recorded at 6.41 USD. The stock hit its 52-week high price on 09/22/15, and 52-week low price on 09/16/16. The percentage movement in the price over the last 12 months remained -85.9%.
Novavax Inc. (NVAX) announced after the close Thursday that a pair of Phase 3 trials of its RSV F Vaccine in older adults did not meet the pre-specified primary or the secondary efficacy objectives and did not demonstrate vaccine efficacy. Prudential Financial Inc. now owns 27,853 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 1,500 shares during the period. “Maternal immunization, for example, may still have potential, however data is years away and we do not expect the stock will get credit for this opportunity in the near-term, and similar thinking will likely apply to the platform and flu opportunities until further data proves such caution is unwarranted”. The firm’s revenue was down 82.1% on a year-over-year basis. The company now has a Return on Equity (ROE) of -112.40% and a Return on Investment (ROI) of -53.60%.
Advertisement
The company’s quick ratio for most recent quarter is 5.10 along with current ratio for most recent quarter of 5.10. The market capitalization of the company is at $349.28 Million.
